PE-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (Site-specific conjugation) (Preservative free)
DMF

Customer Reviews
Cat. No. / Size
Price
Qty
FM3-HPY53-25tests
$450.00
FM3-HPY53-200tests
$2710.00
ETA of in-stock products:2 business days

Product Details

  • Source

    PE-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (FM3-HPY53) is a neutralizing antibody produced via site-specific conjugation of PE to Monoclonal Anti-FMC63 Antibody, Mouse IgG1 under optimal conditions with a proprietary technology. We also carry another proclin-containing version of PE-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (FM3-PY54A2) produced with the same production process except for proclin, and the proclin-containing product has the same performance and can be stored under 2-8 °C for no less than 12 months after reconstitution.

    Besides, we carry another premium grade PE-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Y45) (FM3-PY54G0), produced with the same production process but under more rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. It is designed for cell isolation and cell culture applications in the early preclinical stage.

  • Application

    Flow Cytometry (Evaluation of Anti-CD19 (FMC63 scFv) CAR Expression). Please note that this product is NOT compatible to streptavidin detection system.

  • Clone

    Y45

  • Species

    Mouse

  • Isotype

    Mouse IgG1 | Mouse Kappa

  • Specificity

    Specifically recognizes the antigen-recognition domain of FMC63 derived CARs.

  • Immunogen

    Recombinant FMC63 scFv derived from HEK293 cells

  • Conjugate

    PE

    Excitation Wavelength: 488 nm / 561 nm

    Emission Wavelength: 575 nm

  • Isotype Control

    The Isotype control is sold separately and you can search for Cat. No. DNP-PM1 for product information.

  • Recommended Dilution

    1:50

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 24 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Bioactivity-FACS

     FMC63 FACS

    5e5 of the Anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Cat. No. FM3-HPY53) and PE-Labeled Monoclonal Mouse IgG1 Antibody Isotype Control (Cat. No. DNP-PM1) respectively, PE signal was used to evaluate the binding activity (QC tested).

    Protocol
  •  FMC63 FACS

    Non-specificity of PE-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (Cat. No. FM3-HPY53) binding to CD3+ cells present in human PBMC. Human PBMCs were simultaneously stained with FITC-labeled anti-CD3 antibody and PE-Labeled Monoclonal Anti-FMC63 Antibody, Mouse IgG1 (2 μL of the antibody stock solution corresponds to labeling of 5e5 cells in a final volume of 100 µL), washed and then analyzed with FACS. Both FITC and PE positive signals was used to evaluate the non-specific binding activity to human CD3+ cells (QC tested).

    Protocol

Customer Reviews
Writing Reviews

Background

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background